OTC Markets OTCPK - Delayed Quote ? USD StageZero Life Sciences Ltd. (SZLSF) Follow Compare 0.0244 0.0000 (0.00%) At close: November 15 at 3:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade Order TORONTO, ON / ACCESSWIRE / July 9, 2024 /StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene expression multi-cancer diagnostic for screening for ... ACCESSWIRE ? 4 months ago SZLSF 0.00% StageZero Life Sciences Announces Update on Failure to File Cease Trade Order TORONTO, ON / ACCESSWIRE / May 23, 2024 /StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers ... ACCESSWIRE ? 5 months ago SZLSF 0.00% StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational Update TORONTO, ON / ACCESSWIRE / May 17, 2024 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single ... ACCESSWIRE ? 5 months ago SZLSF 0.00% StageZero Life Sciences Provides an Update on Application for Management Cease Trade Order TORONTO, ON / ACCESSWIRE / April 5, 2024 /StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers ... ACCESSWIRE ? 7 months ago SZLSF 0.00% StageZero Life Sciences Announces Delay to Fourth Quarter and Year End 2023 Financial Results TORONTO, ON / ACCESSWIRE / April 2, 2024 /StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers ... ACCESSWIRE ? 7 months ago SZLSF 0.00% Performance Overview Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return SZLSF S&P/TSX Composite index YTD -17.07% +18.76% 1-Year -27.66% +24.31% 3-Year -90.25% +14.34%
